Category: Press Release

2021.07.29

I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million

2021.07.28

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

2021.07.27

I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange

2021.07.09

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

2021.07.01

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

2021.06.30

I-Mab Honored with Top Rankings by Institutional Investor

2021.06.29

I-Mab Announces Upcoming Participation at July Conference

2021.06.25

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

2021.06.21

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board

2021.06.02

I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab